Month: July 2020

BOCA RATON, Fla., July 13, 2020 (GLOBE NEWSWIRE) — Greenlane Holdings, Inc. (“Greenlane” or “the Company”) (Nasdaq: GNLN), one of the largest global sellers of premium cannabis accessories, child-resistant packaging, supply, and specialty vaporization products, announced today their partnership with NEO Plastics, an innovative packaging company providing an entirely new sustainable solution for discarded plastics. Available this July exclusively to Greenlane customers, NEO Packaging adds an environmentally-friendly offering to Greenlane’s existing packaging lines.NEO Plastics supports landfill gas-to-energy efforts to enhance the end-of-life value of plastic packaging. NEO’s packaging contains an additive that accelerates the natural microbial digestion of the packaging’s material faster than standard plastic alternatives. During...

SOUTH SAN FRANCISCO, July 13, 2020 (GLOBE NEWSWIRE) — Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical stage biotechnology company focused on discovering and developing novel small molecule drugs for the treatment of cancer and other life-threatening diseases, today announced that it has dosed the first patients in its Phase 1b clinical trial of the arginase inhibitor CB-280 in adult patients with cystic fibrosis (CF) and chronic airway infection. The study will evaluate the safety and optimal dose range of CB-280 when added onto existing therapies for CF patients, including CFTR modulators.“We remain committed to advancing our arginase inhibitor clinical development program to fully explore the potential of this new class of therapeutics in a variety of conditions,” said Susan Molineaux, PhD, president and chief executive...

Summit Therapeutics plc (‘Summit’ or the ‘Company’)Summit Announces Publication of Phase 2 Clinical Analyses of Gut Microbiome HealthOxford, UK, and Cambridge, MA, US, July 13, 2020 – Summit Therapeutics plc (NASDAQ: SMMT) today announces the publication of data from the Phase 2 clinical trial of the company’s precision antibiotic, ridinilazole, in development for the treatment of C. difficile infection (‘CDI’) in the American Journal of Physiology – Gastrointestinal and Liver Physiology. The data published in collaboration with researchers at Tufts University and Tufts Medical Center demonstrated that ridinilazole’s microbiome preservation resulted in a gut environment expected to inhibit the growth of C. difficile. In contrast, vancomycin treatment resulted in a gut environment that may more highly favor the growth of C. difficile....

– World-renowned retina specialist to lead EYP-1901 development efforts and support expansion of EyePoint’s ocular disease pipeline –WATERTOWN, Mass., July 13, 2020 (GLOBE NEWSWIRE) — EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing innovative ophthalmic products, today announced the appointment of Jay S. Duker, M.D., as Chief Strategic Scientific Officer. In this newly created role, Dr. Duker will lead the strategic advancement of our research and development efforts, beginning with our lead development candidate EYP-1901 for wet age-related macular degeneration (wet AMD) and new pipeline expansion opportunities under evaluation. In conjunction with this appointment, Dr. Duker has stepped down from the Company’s Board of Directors after four years of...

TORONTO, July 13, 2020 (GLOBE NEWSWIRE) — Hemlo Explorers Inc. (the “Company”) (TSXV: HMLO) is pleased to provide an update on exploration activities that commenced in late May at the Company’s Marathon, Ontario area properties. The Properties are located in the Schreiber-Hemlo greenstone belt that hosts the Hemlo Gold Deposit which has produced over 21 million ounces gold since 1985 and remains in operation today at Barrick’s Williams Mine. The Company has over 38,000 hectares of claims and is the largest claim holder in the Hemlo Camp.The Company initiated a 3D compilation program in early June (see Press Release dated June 22, 2020) at the North Limb Project, with an initial focus on the eastern portion – a geologically complex setting of ultramafic, mafic to felsic metavolcanics, interflow sediments, tuffs and iron formation....

Adding two Boeing 737-400F to fleetFive-year contract with service scheduled to start October 2020Opening a new crew and maintenance base in CincinnatiPHOENIX, July 13, 2020 (GLOBE NEWSWIRE) — Mesa Air Group, Inc. (NASDAQ: MESA) today announced plans to begin providing air cargo service for DHL Express with Boeing 737-400F cargo aircraft. “I’d like to thank all the people at Mesa, their counterparts at DHL and the FAA, who worked hard to bring this program to fruition,” said Captain Mike Ferverda, Senior Vice President of Regulatory Affairs, who is leading Mesa’s 737 certification process. “While much of the industry is challenged given the present COVID environment, we are pleased to expand our growth opportunities with this project.”About Mesa Air Group, Inc.Headquartered in Phoenix, Arizona, Mesa Air Group, Inc. is the holding...

TORONTO, July 13, 2020 (GLOBE NEWSWIRE) — African Gold Group, Inc. (TSX-V: AGG) (“AGG” or the “Company”) is pleased to announce that an updated technical report under National Instrument 43-101 for the definitive feasibility study on Kobada Gold Project has been filed on SEDAR (www.sedar.com), pursuant to the June 17, 2020 press release. “We are very excited to deliver this DFS update, which shows a marked improvement over the 2016 Feasibility Study. We are pleased to announce significantly improved project economics on the back of a large jump in mineral reserves, based on a solid foundation of additional drilling, an updated resource model and a comprehensive metallurgical test work program,” comments Danny Callow, Chief Executive Officer of AGG.“We have worked tirelessly, despite the impact of COVID-19 to deliver...

ROCHESTER, N.Y., July 13, 2020 (GLOBE NEWSWIRE) — Document Security Systems, Inc. (NYSE American: DSS), a multinational company operating businesses focusing on brand protection technology, blockchain security, direct marketing, healthcare, real estate, and securitized digital assets, today announced its Premier Packaging Corp. (Premier) subsidiary signed a three-year contract with one of the world’s largest retailers to supply photo mailing envelopes and folding cartons for prints, posters, canvas decors, photo books, passport photos, and business printing. The contract is valued at approximately $6 million per year and may be renewed for a fourth year.“This is a major win for Premier and solidifies our relationship with a long-term customer,” commented Jason Grady, Chief Operating Officer of DSS. “The fact that we beat out our...

NEW YORK and MAINZ, Germany, July 13, 2020 (GLOBE NEWSWIRE) — Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX, “BioNTech”) today announced that two of the companies’ four investigational vaccine candidates from their BNT162 mRNA-based vaccine program (BNT162b1 and BNT162b2) being developed to help protect against SARS-CoV-2 (the virus that causes COVID-19), received Fast Track designation from the U.S. Food and Drug Administration (FDA). BNT162b1 and BNT162b2 are the two most advanced vaccine candidates in the BNT162 program currently being evaluated in ongoing Phase 1/2 clinical studies in the United States and Germany.Fast Track is a process designed to facilitate the development, and expedite the review, of new drugs and vaccines that are intended to treat or prevent serious conditions that have the potential to address...

NEW YORK und MAINZ, Deutschland, July 13, 2020 (GLOBE NEWSWIRE) — Pfizer Inc. (NYSE: PFE) und BioNTech SE (Nasdaq: BNTX, „BioNTech”) gaben heute bekannt, dass zwei der vier in Entwicklung befindlichen mRNA-basierten Impfstoffkandidaten (BNT162b1 und BNT162b2) gegen SARS-CoV-2 (das Virus, das COVID-19 verursacht) den Fast-Track-Status der US-amerikanischen Arzneimittelbehörde FDA (Food and Drug Administration) erhalten haben. BNT162b1 und BNT162b2 sind die am weitesten fortgeschrittenen Impfstoffkandidaten aus dem BNT162-Impfstoffprogramm, die aktuell in laufenden Phase-1/2-Studien in den USA und Deutschland untersucht werden.Der Fast-Track-Prozess zielt darauf ab, die Entwicklung von neuen Medikamenten und Impfstoffen zu unterstützen, die zur Behandlung oder Prävention von schwerwiegenden Erkrankungen zum Einsatz kommen sollen und...